Curis, Inc.

Acrivon Therapeutics, Inc. brought its initial public offering to the US market a week later than originally planned and at different terms than it proposed a week earlier, but the cancer drug develo

Two companies, Curis and Autolus , have seen their shares rise sharply on promising abstracts of early data to be presented at the European Hematology Association meeting, being held from 9-17 June

Hummingbird Bioscience’s business model is based on the development of novel precision therapies against therapeutically significant, but hard-to-drug, targets. It’s an approach in which investors see

AbCellera Biologics Inc. , 4D Molecular Therapeutics LLC (4DMT) and Nanobiotix SA launched initial public offerings on 10 and 11 December that brought in a combined $774.8m. The AbCellera offering